Meitheal Pharmaceuticals (Meitheal) is pleased to announce the official launch of Heparin Sodium Injection, USP MDV:
- 71288-449-02 – Heparin Sodium Injection, USP 1,000 USP units per mL MDV
- 71288-450-02 - Heparin Sodium Injection, USP 5,000 USP units per mL MDV
- 71288-451-02 - Heparin Sodium Injection, USP 10,000 USP units per mL MDV
ABOUT HEPARIN SODIUM INJECTION, USP MDV
Heparin Sodium Injection is an anticoagulant indicated for
- Prophylaxis and treatment of venous thrombosis and pulmonary embolism
- Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease.
- Atrial fibrillation and embolization
- Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation)
- Prevention of clotting in arterial and cardiac surgery
- Prophylaxis and treatment of peripheral arterial embolism
- Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures.
For full prescribing information, please click on the following link.
Learn more about who we are and what we do at: www.meithealpharma.com.
